



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQB: LVCLY

ASX ANNOUNCEMENT

Living Cell Technologies in Commercial Discussions with APeT Holding BV

10 March 2023 - Sydney, Australia – In connection with the issue of shares and options by Living Cell Technologies Limited (ASX: LCT) (OTC: LVCLY) ("LCT") on 9 March 2023 and in accordance with its disclosure obligations, LCT announces that it is in discussions with Dutch-based pharmaceutical and nutraceutical development company, APeT Holding BV ("APeT"), to explore the suitability of utilising APeT's proprietary controlled release platform. LCT is currently undertaking due diligence on APeT's intellectual property and patents.

The discussions between LCT and APeT have, to this point, been confidential. These discussions are ongoing, and no agreement has been reached on any potential transaction, including but not limited to a partnership, collaboration agreement, licensing arrangement or an acquisition under which LCT would acquire control of APeT.

This lack of agreement extends to all key aspects of the transaction, including the structure of any transaction and the amount and kinds of consideration that would be payable if a transaction ultimately takes place.

A key focus of APeT is the development of treatments for Parkinson's disease using proprietary controlled release oral dosage forms, and so the directors of LCT consider there are potential synergistic and other benefits in a transaction with APeT that are worth exploring in LCT's discussions with APeT.

There is no certainty that the discussions between LCT and APeT will lead to a transaction. LCT will keep the market informed in accordance with its continuous disclosure obligations.

The Board of Directors has authorised this announcement to be given to ASX.

For further information, please contact:

Madhukar Bhalla
Company Secretary

E: mbhalla@lctglobal.com

T: +61 8 9322 6178